FDA warns pharmacies, healthcare staff to avoid drug with aluminum risk

The FDA warned healthcare workers and pharmacies on Feb. 9 not to use an unapproved potassium phosphates drug made by Hospira, a Pfizer company, in pediatric patients because the aluminum exposure can be up to double the agency’s limit. 

Advertisement

Toxic exposure levels to aluminum can cause softening of the bones, reduced bone mineralization, neurological problems, microcytic hypochromic anemia, and a lessened or stopped bile flow, according to the regulatory agency. 

Potassium phosphates injections are used in IV fluids “to correct hypophosphatemia and for parenteral nutrition in adults and pediatric patients,” the FDA said.

The alert recommended two FDA-approved drugs: Fresenius Kabi’s potassium phosphates drug for all ages, and CMP Development’s injection for patients 12 and older who weigh at least 88 pounds and adults who weigh at least 99 pounds.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.